Fatih TEMOÇİN, Behiç ORAL, Çiğdem ATAMAN HATİPOĞLU, Necla TÜLEK, Günay ERTEM, Meliha Çağla SÖNMEZER

The efficacy of oral ribavirin on clinical and laboratory parameters inCrimean?Congo hemorrhagic fever: an observational study from Turkey

Background/aim: In this observational study, the effects of oral ribavirin on clinical and laboratory parameters and blood products use in patients with Crimean Congo hemorrhagic fever (CCHF) were evaluated. Materials and methods: CCHF patients (n = 100) who were hospitalized between 2007 and 2010 were included. Oral ribavirin was administered to 56 patients with symptom duration less than 5 days. Forty-four patients did not receive ribavirin (control group). The patients that received ribavirin in the first 3 days following the initiation of symptoms were designated as Group 1 (n = 29) and the others were designated as Group 2. Results: Ribavirin-treated and untreated groups were similar in terms of demographic and most clinical characteristics. Leukocyte and platelet counts were lower in the ribavirin group than in the control group, but values of prothrombin time, activated partial thromboplastin time, aspartate aminotransferase, creatinine phosphokinase, and lactate dehydrogenase were higher (P = 0.011, P = 0.015, P = 0.001, P = 0.001, P = 0.021, P = 0.019, P = 0.004, respectively). Platelet concentrates use was greater in the ribavirin group (P = 0.01). Conclusion: No positive effects of oral ribavirin on blood products use or clinical or laboratory parameters of CCHF patients were observed. Moreover, no difference was shown between early and late initiation of ribavirin.

PDF

___

1. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64: 145-160.
2. Yılmaz GR, Buzgan T, Torunoglu MA, Safran A, Irmak H, Com S, Uyar Y, Carhan A, Ozkaya E, Ertek M. A preliminary report on Crimean-Congo haemorrhagic fever in Turkey, March-June 2008. Euro Surveill 2008; 13: pii18953.
3. Karti SS, Odabasi Z, Korten V, Yilmaz M, Sonmez M, Caylan R, Akdogan E, Eren N, Koksal I, Ovali E et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis 2004; 10: 1379- 1384.
4. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 78; 2008: 125-131.
5. Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, Senturk GC. Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2012; 12: 805- 811.
6. Paragas J, Whitehouse C, Endy T, Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res 2004; 62: 2125.
7. Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Ölschläger S et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for CrimeanCongo hemorrhagic fever. PLoS Negl Trop Dis 2014; 8: e2804.
8. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo haemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39: 284-287.
9. Elaldi N, Bodur H, Ascioglu S, Celikbas A, Ozkurt Z, Vahaboglu H, Leblebicioglu H, Yilmaz N, Engin A, Sencan M et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 2009; 58: 238-244.
10. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, Gundogdu M, Tasyaran MA. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52: 207-215.
11. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet 1995; 346: 472-475.
12. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36: 1613-1618.
13. Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, Akcay K, Erensoy S, Caylan R, Aydin K. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010; 47: 65-68.
14. Fisgin NT, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009; 28: 929-933.
15. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis 2009; 62: 11-15.
16. Cevik MA, Elaldi N, Akinci E, Onguru P, Erbay A, Buzgan T, Uzun R, Kubar A, Bodur H. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect 2008; 57: 350- 351.
17. Alavi-Naini R, Moghtaderi A, Koohpayeh HR, Sharifi-Mood B, Naderi M, Metanat M, Izadi M. Crimean-Congo hemorrhagic fever in Southeast of Iran. J Infect 2006; 52: 378-382.
18. Bodur H, Erbay A, Akinci E, Onguru P, Bayazıt N, Eren SS, Kubar A. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean Congo hemorrhagic fever. Int J Infect Dis 2011; 15 : e44-47.
19. Ozbey SB, Kader C, Erbay A, Ergonul O. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. VectorBorne Zoonotic Dis 2014; 14: 300-302.
20. Athar MN, Baqai HZ, Ahmad M. Short report: CrimeanCongo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med Hyg 2003; 69: 284-287.
21. Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. Ribavirin for patients Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66: 1215-1222.
22. Soares-Weiser K, Thomas S, Thomson G, Garner P. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis 2010; 10: 207-215.
23. Ergonul O. Crimean-Congo hemorrhagic fever. Lancet Infect Dis 2006; 6: 203-214.
24. Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, Torunoglu MA. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009; 13: 380-386.
25. Jahromi MK. Crimean-Congo hemorrhagic fever-treatment and preventive strategies. Int J Infect 2014; 1: e20310.